This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.


Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


1b3o

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
(New page: 200px<br /> <applet load="1b3o" size="450" color="white" frame="true" align="right" spinBox="true" caption="1b3o, resolution 2.90&Aring;" /> '''TERNARY COMPLEX OF ...)
Line 1: Line 1:
-
[[Image:1b3o.gif|left|200px]]<br />
+
[[Image:1b3o.gif|left|200px]]<br /><applet load="1b3o" size="350" color="white" frame="true" align="right" spinBox="true"
-
<applet load="1b3o" size="450" color="white" frame="true" align="right" spinBox="true"
+
caption="1b3o, resolution 2.90&Aring;" />
caption="1b3o, resolution 2.90&Aring;" />
'''TERNARY COMPLEX OF HUMAN TYPE-II INOSINE MONOPHOSPHATE DEHYDROGENASE WITH 6-CL-IMP AND SELENAZOLE ADENINE DINUCLEOTIDE'''<br />
'''TERNARY COMPLEX OF HUMAN TYPE-II INOSINE MONOPHOSPHATE DEHYDROGENASE WITH 6-CL-IMP AND SELENAZOLE ADENINE DINUCLEOTIDE'''<br />
==Overview==
==Overview==
-
Inosine monophosphate dehydrogenase (IMPDH) controls a key metabolic step, in the regulation of cell growth and differentiation. This step is the, NAD-dependent oxidation of inosine 5' monophosphate (IMP) to xanthosine 5', monophosphate, the rate-limiting step in the synthesis of the guanine, nucleotides. Two isoforms of IMPDH have been identified, one of which, (type II) is significantly up- regulated in neoplastic and differentiating, cells. As such, it has been identified as a major target in antitumor and, immunosuppressive drug design. We present here the 2.9-A structure of a, ternary complex of the human type II isoform of IMPDH. The complex, contains the substrate analogue 6-chloropurine riboside 5'-monophosphate, (6-Cl-IMP) and the NAD analogue selenazole-4-carboxamide adenine, dinucleotide, the selenium derivative of the active metabolite of the, antitumor drug tiazofurin. The enzyme forms a homotetramer, with the, dinucleotide binding at the monomer-monomer interface. The 6, chloro-substituted purine base is dehalogenated, forming a covalent adduct, at C6 with Cys-331. The dinucleotide selenazole base is stacked against, the 6-Cl-IMP purine ring in an orientation consistent with the B-side, stereochemistry of hydride transfer seen with NAD. The adenosine end of, the ligand interacts with residues not conserved between the type I and, type II isoforms, suggesting strategies for the design of isoform-specific, agents.
+
Inosine monophosphate dehydrogenase (IMPDH) controls a key metabolic step in the regulation of cell growth and differentiation. This step is the NAD-dependent oxidation of inosine 5' monophosphate (IMP) to xanthosine 5' monophosphate, the rate-limiting step in the synthesis of the guanine nucleotides. Two isoforms of IMPDH have been identified, one of which (type II) is significantly up- regulated in neoplastic and differentiating cells. As such, it has been identified as a major target in antitumor and immunosuppressive drug design. We present here the 2.9-A structure of a ternary complex of the human type II isoform of IMPDH. The complex contains the substrate analogue 6-chloropurine riboside 5'-monophosphate (6-Cl-IMP) and the NAD analogue selenazole-4-carboxamide adenine dinucleotide, the selenium derivative of the active metabolite of the antitumor drug tiazofurin. The enzyme forms a homotetramer, with the dinucleotide binding at the monomer-monomer interface. The 6 chloro-substituted purine base is dehalogenated, forming a covalent adduct at C6 with Cys-331. The dinucleotide selenazole base is stacked against the 6-Cl-IMP purine ring in an orientation consistent with the B-side stereochemistry of hydride transfer seen with NAD. The adenosine end of the ligand interacts with residues not conserved between the type I and type II isoforms, suggesting strategies for the design of isoform-specific agents.
==About this Structure==
==About this Structure==
-
1B3O is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with CPR, SAE and UNX as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/IMP_dehydrogenase IMP dehydrogenase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=1.1.1.205 1.1.1.205] Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=1B3O OCA].
+
1B3O is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with <scene name='pdbligand=CPR:'>CPR</scene>, <scene name='pdbligand=SAE:'>SAE</scene> and <scene name='pdbligand=UNX:'>UNX</scene> as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/IMP_dehydrogenase IMP dehydrogenase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=1.1.1.205 1.1.1.205] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1B3O OCA].
==Reference==
==Reference==
Line 15: Line 14:
[[Category: IMP dehydrogenase]]
[[Category: IMP dehydrogenase]]
[[Category: Single protein]]
[[Category: Single protein]]
-
[[Category: Colby, T.D.]]
+
[[Category: Colby, T D.]]
-
[[Category: Goldstein, B.M.]]
+
[[Category: Goldstein, B M.]]
-
[[Category: Strickler, M.D.]]
+
[[Category: Strickler, M D.]]
[[Category: Vanderveen, K.]]
[[Category: Vanderveen, K.]]
[[Category: CPR]]
[[Category: CPR]]
Line 27: Line 26:
[[Category: impdh]]
[[Category: impdh]]
-
''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Mon Nov 12 16:05:24 2007''
+
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 11:51:06 2008''

Revision as of 09:51, 21 February 2008


1b3o, resolution 2.90Å

Drag the structure with the mouse to rotate

TERNARY COMPLEX OF HUMAN TYPE-II INOSINE MONOPHOSPHATE DEHYDROGENASE WITH 6-CL-IMP AND SELENAZOLE ADENINE DINUCLEOTIDE

Overview

Inosine monophosphate dehydrogenase (IMPDH) controls a key metabolic step in the regulation of cell growth and differentiation. This step is the NAD-dependent oxidation of inosine 5' monophosphate (IMP) to xanthosine 5' monophosphate, the rate-limiting step in the synthesis of the guanine nucleotides. Two isoforms of IMPDH have been identified, one of which (type II) is significantly up- regulated in neoplastic and differentiating cells. As such, it has been identified as a major target in antitumor and immunosuppressive drug design. We present here the 2.9-A structure of a ternary complex of the human type II isoform of IMPDH. The complex contains the substrate analogue 6-chloropurine riboside 5'-monophosphate (6-Cl-IMP) and the NAD analogue selenazole-4-carboxamide adenine dinucleotide, the selenium derivative of the active metabolite of the antitumor drug tiazofurin. The enzyme forms a homotetramer, with the dinucleotide binding at the monomer-monomer interface. The 6 chloro-substituted purine base is dehalogenated, forming a covalent adduct at C6 with Cys-331. The dinucleotide selenazole base is stacked against the 6-Cl-IMP purine ring in an orientation consistent with the B-side stereochemistry of hydride transfer seen with NAD. The adenosine end of the ligand interacts with residues not conserved between the type I and type II isoforms, suggesting strategies for the design of isoform-specific agents.

About this Structure

1B3O is a Single protein structure of sequence from Homo sapiens with , and as ligands. Active as IMP dehydrogenase, with EC number 1.1.1.205 Full crystallographic information is available from OCA.

Reference

Crystal structure of human type II inosine monophosphate dehydrogenase: implications for ligand binding and drug design., Colby TD, Vanderveen K, Strickler MD, Markham GD, Goldstein BM, Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3531-6. PMID:10097070

Page seeded by OCA on Thu Feb 21 11:51:06 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools